⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21916365 | 0.83 | CCR1 (0.56) | — | |
| SCHEMBL19018468 | 0.80 | NPC1 (0.41) | — | |
| SCHEMBL1741746 | 0.73 | — | — | |
| Abametapir SCHEMBL29374261 | 0.71 | CCR1 (1.00) | — | |
| SCHEMBL31030 | 0.71 | — | — | |
| SCHEMBL31218494 | 0.71 | — | — | |
| Abametapir SCHEMBL351152 | 0.71 | CCR1 (1.00) | — | |
| SCHEMBL31243289 | 0.71 | — | — | |
| SCHEMBL10765894 | 0.71 | HDAC6 (0.60) | — | |
| SCHEMBL198094 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 576 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118344287-B | Preparation method of pirfenidone | 山东方明药业集团股份有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-118344287-A | Preparation method of pirfenidone | 山东方明药业集团股份有限公司 | 2024-07-16 | — | — | CN | claimed |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2025-12-25 | — | — | US | disclosed |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4556476-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2025-05-21 | — | — | EP | disclosed |
| CN-118344287-B | Preparation method of pirfenidone | 山东方明药业集团股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20240239778-A1 | GRISEOFULVIN COMPOUND AND PHARMACEUTICAL USE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-07-18 | — | — | US | disclosed |
| CN-118344287-A | Preparation method of pirfenidone | 山东方明药业集团股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118344287-A | Preparation method of pirfenidone | 山东方明药业集团股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| WO-2024014885-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | 일동제약(주) | 2024-01-18 | — | — | WO | disclosed |
| EP-1140946-A2 | QUINOLINE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2001-10-10 | — | — | EP | disclosed |
| EP-1089998-A2 | EPOTHILONE DERIVATIVES AND THEIR SYNTHESIS AND USE | Novartis AG (CH) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000035919-A2 | QUINOLINE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2000-06-22 | — | — | WO | disclosed |
| WO-1999067252-A2 | EPOTHILONE DERIVATIVES AND THEIR SYNTHESIS AND USE | NOVARTIS AG (CH) | 1999-12-29 | — | — | WO | disclosed |
| EP-0247381-B1 | 5-FLUROROURACIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-04 | — | — | EP | disclosed |
| US-5118694-A | Hypotensive agents; treatment for cardiovascular and muscular disorders | HOFFMANN-LA ROCHE INC. (US) | 1992-06-02 | — | — | US | disclosed |
| US-5047521-A | Anticarcinogenic agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| US-4971982-A | HYPOTENSIVE AGENTS, CARDIOVASCULAR DISORDERS, SMOOTH MUSCLE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1990-11-20 | — | — | US | disclosed |
| EP-0247381-A2 | 5-flurorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-12-02 | — | — | EP | disclosed |